Hologic (NASDAQ:HOLX) Earns Hold Rating from Analysts at Jefferies Financial Group

Analysts at Jefferies Financial Group assumed coverage on shares of Hologic (NASDAQ:HOLX) in a report released on Tuesday,Briefing.com Automated Import reports. The firm set a “hold” rating and a $85.00 price target on the medical equipment provider’s stock. Jefferies Financial Group’s target price suggests a potential upside of 12.15% from the stock’s previous close.

A number of other research firms also recently weighed in on HOLX. JPMorgan Chase & Co. boosted their price target on shares of Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Royal Bank of Canada increased their price target on Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research note on Tuesday, November 5th. UBS Group lifted their price objective on Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Citigroup lowered Hologic from a “buy” rating to a “neutral” rating and cut their target price for the company from $95.00 to $85.00 in a research note on Tuesday, October 1st. Finally, StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, Hologic presently has an average rating of “Moderate Buy” and an average price target of $89.50.

Hologic Stock Up 0.6 %

Shares of HOLX opened at $75.79 on Tuesday. The business’s fifty day moving average price is $79.69 and its two-hundred day moving average price is $78.58. The firm has a market capitalization of $17.20 billion, a price-to-earnings ratio of 22.76, a PEG ratio of 2.37 and a beta of 0.96. Hologic has a 52 week low of $68.15 and a 52 week high of $84.67. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.01. The business had revenue of $987.90 million for the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter last year, the business earned $0.89 earnings per share. On average, analysts predict that Hologic will post 4.28 earnings per share for the current year.

Insider Activity at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.75% of the stock is owned by insiders.

Hedge Funds Weigh In On Hologic

A number of large investors have recently added to or reduced their stakes in HOLX. Wolff Wiese Magana LLC bought a new stake in shares of Hologic in the third quarter valued at about $25,000. Innealta Capital LLC acquired a new stake in Hologic in the 2nd quarter valued at approximately $25,000. First Horizon Advisors Inc. lifted its stake in Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 134 shares in the last quarter. Sunbelt Securities Inc. acquired a new position in Hologic during the 2nd quarter worth approximately $37,000. Finally, Cromwell Holdings LLC raised its holdings in shares of Hologic by 330.2% in the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 416 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.